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Alcoholic liver disease (ALD) is a growing cause of liver-related morbidity and mortality 
worldwide.1 Rates of hazardous drinking are increasing, the age of onset of drinking is 
decreasing, and more women are drinking heavily.2 With better control of chronic hepatitis 
B and C, ALD is again becoming one of the commonest causes of chronic liver disease.1 
ALD comprises a spectrum of clinical and pathologic features, ranging from minimal 
abnormalities, such as steatosis, to more severe liver disease associated with inflammation, 
as in alcoholic hepatitis (AH), advanced fibrosis, or cirrhosis.3 Many patients who drink 
excessively are diagnosed when their liver disease decompensates, suggesting an 
asymptomatic period of fibrosis or compensated cirrhosis.4 If so, this would support a 
screening strategy to identify those at risk. In this issue of Gastroenterology,5 Thiele et al 
report on the usefulness of transient elastography (TE) using Fibroscan or 2-dimensional 
shear wave elastography (2D-SWE, Aixplorer) in detecting fibrosis/cirrhosis in heavy 
drinkers, using liver biopsy as the gold standard.
Screening for ALD makes intuitive sense. The National Institute on Alcohol Abuse and 
Alcoholism reported that there are 16.6 million American adults with alcohol use disorders 
(AUDs). The public health approach to hazardous drinking is early screening, brief 
intervention, and referral to treatment starting in adolescence.3 The main target of this 
strategy is those drinking at hazardous but not yet dependent levels, when success rates are 
best.6 This approach is not only cost effective, but actually cost saving, because screening is 
rapid and inexpensive.6 Screening for ALD is more complicated but may be warranted. 
Jinjuvadia and Liangpunsakul7 reported an increase in total number of AH-related 
hospitalizations from approximately 250,000 in 2002 to approximately 326,000 in 2010. The 
majority of patients with AH have fibrosis or cirrhosis on biopsy,8 a fairly high percentage 
are unable to abstain, and thus a large number of these patients will likely progress to 
cirrhosis.
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Although ALD is common in absolute terms, it seems to be an uncommon consequence of 
AUDs.9 Based on these epidemiologic data, AH patients may represent approximately 1%–
2% of the total numbers of heavy drinkers.7 Cirrhosis deaths affect only 0.2% of those with 
AUDs, and only about 10%–15% of people with AUDs develop cirrhosis in their lifetime.7 
Thus, ALD develops in only a small minority of excessive drinkers; this low prevalence of 
disease among a large population of at-risk individuals makes cost-effective screening more 
difficult, especially given the social and economic barriers patients with AUDs have that 
impede linkage with providers.10
An approach used to guide screening is risk stratification. Unfortunately, there are no 
clinical parameters or diagnostic tests that can accurately predict the development of ALD. 
Risk factors include female sex, nutritional deficiency, dietary components (type of fat and 
caffeine), genetic factors (eg, PNPLA3 genotype), smoking, and obesity, but we lack a 
model that accurately predicts ALD, nor do quantity, frequency, pattern or type of alcohol 
consumed predict risk.11 Laboratory tests such as aspartate transaminase to alanine 
transaminase ratio are not useful as most subjects with AUDs do not have a high ratio or 
even increased aminotransferase levels.12
A possible approach to early identification of ALD is TE. Thiele’s group recruited heavy 
drinkers from 2 general venues in Denmark, based on the pretest probability of alcohol-
related cirrhosis: liver clinics (high pretest risk; n = 128) and municipal alcohol 
rehabilitation centers (low pretest risk; n = 71).5 Nearly all of these patients underwent liver 
biopsy on the same day as TE. Patients referred to the liver clinics with obvious cirrhosis 
were excluded. Thirty-nine (30%) and 33 (26%) of high pretest risk subjects and 9 (12%) 
and 3 (4%) of the low pretest group had advanced fibrosis and cirrhosis, respectively.5 About 
one-half of the subjects were abstinent at enrollment, and of these, 70% had stopped 
drinking for <12 months (median, 10 weeks). The results of this study were as follows. (1) 
Fibroscan and 2D-SWE had a high diagnostic accuracy for advanced fibrosis and cirrhosis in 
heavy drinkers and the performance of the 2 methods was comparable. (2) The optimal 
cutoff values for advanced fibrosis and cirrhosis were different depending on the pretest 
probability of alcohol-related cirrhosis. (3) Both methods had very high negative predictive 
value. Only 2 of 199 patients with low liver stiffness (LS) had cirrhosis on biopsy. However, 
the positive predictive value was less impressive, ranging from 49% to 73%, depending on 
the pretest probability of cirrhosis. (4) Both methods correlated well with the collagen 
proportionate area determined on the liver biopsy samples. Finally, (5) by including an 
additional cohort of patients with decompensated alcohol-related cirrhosis (Child-Pugh 
classes B and C) enrolled from a hospital in Germany, both TE and 2D-SWE were excellent 
in differentiating subjects with Child-Pugh class A from those with B and C disease, but not 
Child B from C.
This study is perhaps the largest to explore the use of Fibroscan and 2D-SWE to screen for 
advanced fibrosis and cirrhosis, especially in heavy drinkers without other evidence of 
ALD.5 A few observations deserve comment. First, contrary to other reports,13,14 this study 
did not observe an effect of heavy drinking on LS. However, this was based entirely on the 
patients’ self-reported alcohol use, and only 11 patients admitted to heavy drinking. A 
previous study showed LS decreased significantly in nearly one-half of heavy drinkers after 
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7 days of abstinence, which was ensured by hospitalizing the patient.13 Second, the optimal 
cutoff for LS to predict advanced fibrosis and cirrhosis is considerably higher than that for 
hepatitis C virus.15 Thiele et al5 suggested that it may relate to the different pattern of 
fibrosis between ALD and hepatitis C virus. Last, they suggested the LS in advanced ALD 
might be influenced by cholangiocyte injury, because LS correlated with bilirubin and 
glutamyl transpeptidase.5 Although extrahepatic cholestasis can increase LS, irrespective of 
fibrosis,16 it is not clear why another marker of cholestasis, alkaline phosphatase, was not 
correlated. It is possible that the association with GGT reflects undisclosed heavy alcohol 
use by the patients, which in turn would suggest that heavy alcohol use indeed increases the 
LS. Another possibility is an unrecognized association between AH and LS; the authors are 
urged to review their biopsy specimens to test this hypothesis. Either way, it seems the most 
reliable estimates of LS will be obtained while the patient is abstinent.
The findings from this study are an important impetus for attempts at identifying patients at 
an earlier stage of ALD. Fully 17% of the low-risk heavy drinking patients had advanced 
fibrosis or cirrhosis; this unexpectedly high yield compares favorably with other conditions 
in which screening is practiced (lung cancer, prevalence of 0.5%–2.2% in smokers17; 
hepatoma, 3%–8% per year in patients with cirrhosis from hepatitis C and B virus 
infection18). Early identification of such patients will only be valuable if we can influence 
their drinking behavior with either cognitive or pharmacologic treatments, because we lack 
treatment that prevents liver injury with continued drinking. There is evidence that this is 
possible: alerting patients of possible ALD (using blood tests for fibrosis) reduced their 
drinking levels at their 1-year follow-up.19 One could envision tailoring brief or more 
intensive treatment to patients with evidence of fibrosis from TE. For those with cirrhosis, 
there is still considerable impact of reduced drinking on survival and outcome. The 5-year 
survival rate for people with cirrhosis who stop drinking is about 90%, compared with 70% 
for those who continue to drink.20 Even after the development of complications from 
cirrhosis, abstinence is essential, because the survival rate is approximately 60% for those 
who stop drinking and 35% for those who do not.20
Much information would be needed before widespread screening with TE could be 
considered. Knowledge of the alcohol drinking trajectory in the low risk patients of the 
Thiele study5 might help to determine when screening is needed, that is, what was the 
quantity and duration of heavy alcohol use which was associated with advanced fibrosis and 
cirrhosis? Longitudinal studies of heavy drinkers would help us to understand the time 
course of the development of fibrosis. It is assumed that patients have gradual development 
of fibrosis, but it is possible that it develops rapidly, for instance, during a clinical or 
subclinical episode of AH. This might explain why we so often identify the patients only 
when they decompensate, and would seriously impact the ability of screening for fibrosis to 
prevent cirrhosis. Other important outstanding questions include the following. Can we 
confirm that early detection of advanced fibrosis influences the patient’s ability to abstain 
long term? Does early detection of advanced fibrosis and abstinence result in reversal of 
fibrosis, as is seen with the control of chronic viral hepatitis? And, of course, does early 
detection of advanced fibrosis and cirrhosis prolong the patients’ lives, reduce medical 
expenses, and improve quality of life? Nonetheless, the dissemination of TE technology may 
provide a way for primary care physicians, hepatologists, and addiction specialists to focus 
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care on patients with AUDs at the greatest risk of advanced liver disease, and reduce this 
serious complication of heavy alcohol use.
Acknowledgments
Funding
This study is partly supported by 1I01CX000361-01 from the Veterans Affairs Research and Administration, and 
W81XWH-12-1-0497 from United States Department of Defense (to S.L), 5P60AA007611 and U01AA021840 (to 
DWC).
References
1. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013; 
59:160–168. [PubMed: 23511777] 
2. World Health Organization (WHO). Global status report on alcohol and health. 2014. Available 
from: www.who.int/substance_abuse/publications/global_alcohol_report/en/
3. Thiele M, Detlefsen S, Møller LS, et al. Transient and 2-dimensional shear-wave elastography 
provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology. 2016; 
150:123–133. [PubMed: 26435270] 
4. Moyer A, Finney JW. Brief interventions for alcohol problems: factors that facilitate 
implementation. Alcohol Res Health. 2004; 28:44–50. [PubMed: 19006991] 
5. Zheng SH, Li YM, Chen SH, et al. Alcoholic liver disease. Are there any differences between China 
and Western countries in clinical features? Saudi Med J. 2014; 35:753–756. [PubMed: 25028237] 
6. Agerwala SM, McCance-Katz EF. Integrating screening, brief intervention, and referral to treatment 
(SBIRT) into clinical practice settings: a brief review. J Psychoactive Drugs. 2012; 44:307–317. 
[PubMed: 23210379] 
7. Jinjuvadia R, Liangpunsakul S. Trends in alcoholic hepatitis-related hospitalizations, financial 
burden, and mortality in the United States. J Clin Gastroenterol. 2015; 49:506–511. [PubMed: 
25198164] 
8. Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of 
patients with alcoholic hepatitis. Gastroenterology. 2014; 146:1231–1239. [PubMed: 24440674] 
9. Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns 
on liver disease. Hepatology. 2007; 46:2032–2039. [PubMed: 18046720] 
10. Harris AH, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived 
treatment barriers and action strategies among Veterans Health Administration service providers. 
Psychol Serv. 2013; 10:410–419. [PubMed: 23356858] 
11. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. 
Gastroenterology. 2011; 141:1572–1585. [PubMed: 21920463] 
12. Gough G, Heathers L, Puckett D, et al. The utility of commonly used laboratory tests to screen for 
excessive alcohol use in clinical practice. Alcohol Clin Exp Res. 2015; 39:1493–1500. [PubMed: 
26110815] 
13. Trabut JB, Thepot V, Nalpas B, et al. Rapid decline of liver stiffness following alcohol withdrawal 
in heavy drinkers. Alcohol Clin Exp Res. 2012; 36:1407–1411. [PubMed: 22404692] 
14. Bardou-Jacquet E, Legros L, Soro D, et al. Effect of alcohol consumption on liver stiffness 
measured by transient elastography. World J Gastroenterol. 2013; 19:516–522. [PubMed: 
23382630] 
15. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, 
APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 
2005; 128:343–350. [PubMed: 15685546] 
16. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness 
(FibroScan) irrespective of fibrosis. Hepatology. 2008; 48:1718–1723. [PubMed: 18836992] 
17. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed 
tomographic screening. N Engl J Med. 2011; 365:395–409. [PubMed: 21714641] 
LIANGPUNSAKUL and CRABB Page 4





















18. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 
53:1020–1022. [PubMed: 21374666] 
19. Sheron N, Moore M, O’Brien W, et al. Feasibility of detection and intervention for alcohol-related 
liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS). Br J 
Gen Pract. 2013; 63:e698–e705. [PubMed: 24152485] 
20. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health. 
2003; 27:209–219. [PubMed: 15535449] 
LIANGPUNSAKUL and CRABB Page 5
Gastroenterology. Author manuscript; available in PMC 2017 July 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
